FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC

The FDA has approved zidesamtinib (Jideytro; GSK), a ROS1-selective kinase inhibitor, for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who previously received a ROS1 tyrosine kinase inhibitor (TKI). The approval arrived ahead of the drug's original September 18, 2026, target action date and marks the company's first approval in lung cancer. The decision follows the FDA's Breakthrough Therapy and Orphan Drug designations for zidesamtinib, both of which are intended to expedite development of therapies addressing serious, underserved conditions.^1,2

“For patients, the goal is not just more time but quality time to live life as normally as possible while on treatment. The ROS1-positive community is deeply invested in advancing care with treatments that are effective and tolerable. Today's approval gives patients and their doctors an important new option and represents meaningful progress for our community,” Janet Freeman-Daily, co-founder and president of The ROS1ders, said in a news release.¹

What Is Zidesamtinib

Zidesamtinib was designed to overcome key efficacy and tolerability limitations of earlier ROS1 inhibitors. Its next-generation structure combines high target selectivity, broad coverage of ROS1 resistance mutations, and blood-brain barrier penetration intended to control disease that has spread to the central nervous system (CNS). ROS1-positive NSCLC affects an estimated 50,000 individuals worldwide each year, often nonsmokers in their 40s and 50s who may remain on treatment for years given the chronic nature of the disease. Zidesamtinib is the fourth ROS1 TKI to reach approval, following crizotinib, entrectinib, and the more recently approved next-generation agents repotrectinib and taletrectinib, reflecting an increasingly crowded but still evolving treatment class.^1,3

Clinical Trials/Evidence

The approval was based on the global, single-arm ARROS-1 phase 1/2 trial (NCT05118789), which evaluated zidesamtinib in patients with advanced ROS1-positive NSCLC previously treated with a ROS1 TKI. Among 117 evaluable patients, the objective response rate was 44% (95% CI, 34%-53%), with duration-of-response rates of 82% at 6 months and 69% at 12 months. Responses were observed even among heavily pretreated patients and those with ROS1 resistance mutations or brain metastases.¹

In a related dataset, intracranial response rate reached 48% among patients with measurable CNS lesions at baseline, underscoring the drug's CNS-penetrant design. The most common adverse reactions occurring in at least 15% of the pooled safety population of 446 patients were edema, peripheral neuropathy, constipation, fatigue, and dyspnea.^1,2

Clinical Implications

For pharmacists, zidesamtinib's approval adds a next-generation option to a ROS1 TKI landscape that has evolved rapidly since crizotinib's (Xalkori; Pfizer) initial 2016 approval. Its brain-penetrant design may be particularly relevant when counseling patients with CNS involvement, since disease progression in the brain remains a leading cause of treatment failure in ROS1-positive NSCLC. Pharmacists should anticipate questions about drug interactions, as kinase inhibitors are frequently substrates of CYP3A4 and may be affected by concomitant use of strong inhibitors or inducers, and should reinforce adherence given the drug's role as later-line therapy following prior TKI failure. Monitoring for peripheral neuropathy and fluid retention, the most frequently reported toxicities, should be incorporated into routine follow-up counseling, alongside patient education on symptom reporting to support early dose-modification decisions and to help patients maintain quality of life while on long-term therapy.^1,3

Conclusion

Zidesamtinib continues to be studied in ARROS-1, including a cohort evaluating first-line use in ROS1 TKI-naive patients, which could expand its role earlier in the treatment sequence if supported by future data.¹

GSK is also advancing additional Nuvalent-derived candidates, including neladalkib for ALK-altered NSCLC, currently under FDA review with a target decision date of November 27, 2026, and NVL-330, an investigational treatment for HER2-altered NSCLC. Alongside these programs, the company is developing risvutatug rezetecan, a B7-H3-targeted antibody-drug conjugate with recently reported positive phase 3 data in relapsed small-cell lung cancer, suggesting a broader pipeline of targeted lung cancer therapies pharmacists may encounter in formularies over the coming years as precision oncology continues to expand.¹

REFERENCES

1. Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer. News release. GSK; July 22, 2026. Accessed July 22, 2026. https://www.gsk.com/en-gb/media/press-releases/jideytro-zidesamtinib-approved-in-the-us-for-previously-treated-ros1-positive-non-small-cell-lung-cancer/

2. FDA accepts NDA for zidesamtinib in advanced ROS1+ NSCLC. Targeted Oncology. Updated November 20, 2025. Accessed July 22, 2026. https://www.targetedonc.com/view/fda-accepts-nda-for-zidesamtinib-in-advanced-ros1-nsclc

3. Current and emerging treatment strategies for advanced ROS1-positive NSCLC. Cancer Therapy Advisor. April 2026. Accessed July 22, 2026. https://www.cancertherapyadvisor.com/cch/advanced-ros1-positive-non-small-cell-lung-cancer-tki-zidesamtinib/